{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:53:46Z","timestamp":1785196426941,"version":"3.55.0"},"reference-count":197,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ41007"],"award-info":[{"award-number":["2021JJ41007"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021RC2013"],"award-info":[{"award-number":["2021RC2013"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022LNJJ11"],"award-info":[{"award-number":["2022LNJJ11"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Science and Technology Innovation Program of Hunan Province","award":["2021JJ41007"],"award-info":[{"award-number":["2021JJ41007"]}]},{"name":"the Science and Technology Innovation Program of Hunan Province","award":["2021RC2013"],"award-info":[{"award-number":["2021RC2013"]}]},{"name":"the Science and Technology Innovation Program of Hunan Province","award":["2022LNJJ11"],"award-info":[{"award-number":["2022LNJJ11"]}]},{"name":"the Clinical Research Foundation of the National Clinical Research Center for Geriatric Disorders","award":["2021JJ41007"],"award-info":[{"award-number":["2021JJ41007"]}]},{"name":"the Clinical Research Foundation of the National Clinical Research Center for Geriatric Disorders","award":["2021RC2013"],"award-info":[{"award-number":["2021RC2013"]}]},{"name":"the Clinical Research Foundation of the National Clinical Research Center for Geriatric Disorders","award":["2022LNJJ11"],"award-info":[{"award-number":["2022LNJJ11"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pseudomyxoma peritonei (PMP) is a rare disease characterized by extensive peritoneal implantation and mass secretion of mucus after primary mucinous tumors of the appendix or other organ ruptures. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the preferred treatment, with excellent efficacy and safety, and is associated with breakthrough progress in long-term disease control and prolonged survival. However, the high recurrence rate of PMP is the key challenge in its treatment, which limits the clinical application of multiple rounds of CRS-HIPEC and does not benefit from conventional systemic chemotherapy. Therefore, the development of alternative therapies for patients with refractory or relapsing PMP is critical. The literature related to PMP research progress and treatment was searched in the Web of Science, PubMed, and Google Scholar databases, and a literature review was conducted. The overview of the biological research, treatment status, potential therapeutic strategies, current research limitations, and future directions associated with PMP are presented, focuses on CRS-HIPEC therapy and alternative or combination therapy strategies, and emphasizes the clinical transformation prospects of potential therapeutic strategies such as mucolytic agents and targeted therapy. It provides a theoretical reference for the treatment of PMP and the main directions for future research.<\/jats:p>","DOI":"10.3390\/cancers16071406","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T08:42:34Z","timestamp":1712133754000},"page":"1406","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Progress in Biological Research and Treatment of Pseudomyxoma Peritonei"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7114-5122","authenticated-orcid":false,"given":"Xi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Geriatric Surgery, Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Surgery, Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Geriatric Surgery, Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process","volume":"40","author":"Carr","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_2","first-page":"252","article-title":"Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method","volume":"28","author":"Carr","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4240\/wjgs.v10.i5.49","article-title":"Approach to pseudomyxoma peritonei","volume":"10","author":"Rizvi","year":"2018","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/02656736.2017.1310938","article-title":"Pseudomyxoma peritonei: Natural history and treatment","volume":"33","author":"Mittal","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejso.2007.04.002","article-title":"Appendiceal neoplasms and pseudomyxoma peritonei: A population based study","volume":"34","author":"Smeenk","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_6","first-page":"115","article-title":"Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature","volume":"1","author":"Zhong","year":"2012","journal-title":"Intractable Rare Dis. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/1096-9098(200012)75:4<270::AID-JSO9>3.0.CO;2-V","article-title":"Unusual origins of Pseudomyxoma peritonei","volume":"75","author":"Witkamp","year":"2000","journal-title":"J. Surg. Oncol."},{"key":"ref_8","first-page":"5826214","article-title":"Pseudomyxoma Peritonei Originating from Transverse Colon Mucinous Adenocarcinoma: A Case Report and Literature Review","volume":"2020","author":"Gong","year":"2020","journal-title":"Gastroenterol. Res. Pr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.pan.2020.06.008","article-title":"Immunohistochemical staining as supportive diagnostic tool for pseudomyxoma peritonei arising from intraductal papillary mucinous neoplasm: A report of two cases and literature review","volume":"20","author":"Kataoka","year":"2020","journal-title":"Pancreatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00000478-199105000-00001","article-title":"Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix","volume":"15","author":"Young","year":"1991","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/SLA.0b013e318269d680","article-title":"Improving the AJCC\/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histological grade","volume":"257","author":"Overman","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","article-title":"Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review","volume":"30","author":"Bradley","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13023-021-01723-6","article-title":"Consensuses and controversies on pseudomyxoma peritonei: A review of the published consensus statements and guidelines","volume":"16","author":"Lin","year":"2021","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s10350-005-0045-5","article-title":"Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: A prospective study","volume":"48","author":"Loungnarath","year":"2005","journal-title":"Dis. Colon. Rectum."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.5858\/arpa.2011-0034-RA","article-title":"Mucinous neoplasms of the appendix and peritoneum","volume":"135","author":"Panarelli","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/00000478-199512000-00006","article-title":"Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u201cpseudomyxoma peritonei\u201d","volume":"19","author":"Ronnett","year":"1995","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","unstructured":"Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_18","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery","volume":"156","author":"Kusamura","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_21","first-page":"281","article-title":"Report on the 9(th) International Congress on Peritoneal Surface Malignancies","volume":"11","author":"Li","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jso.21054","article-title":"Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei)","volume":"98","author":"Moran","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bjs5.97","article-title":"Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"3","author":"Mercier","year":"2019","journal-title":"BJS Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bjc.6604522","article-title":"A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei","volume":"99","author":"Farquharson","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s10147-019-01592-x","article-title":"Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei","volume":"25","author":"Hiraide","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1634\/theoncologist.2014-0106","article-title":"FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma","volume":"19","author":"Pietrantonio","year":"2014","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Prabhu, A., Brandl, A., Wakama, S., Sako, S., Ishibashi, H., Mizumoto, A., Takao, N., Noguchi, K., Motoi, S., and Ichinose, M. (2020). Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei-A Novel Treatment Approach. Cancers, 12.","DOI":"10.3390\/cancers12082212"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.clcc.2019.03.002","article-title":"Metronomic Capecitabine with Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei","volume":"18","author":"Raimondi","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/gm559","article-title":"Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin","volume":"6","author":"Alakus","year":"2014","journal-title":"Genome Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/COC.0000000000000376","article-title":"Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy","volume":"41","author":"Gleeson","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/cam4.542","article-title":"Molecular profiles of high-grade and low-grade pseudomyxoma peritonei","volume":"4","author":"Noguchi","year":"2015","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1002\/ijc.29245","article-title":"Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry","volume":"136","author":"Nummela","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jmoldx.2018.05.002","article-title":"Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei","volume":"20","author":"Pengelly","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/annonc\/mdw314","article-title":"Toward the molecular dissection of peritoneal pseudomyxoma","volume":"27","author":"Pietrantonio","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Saarinen, L., Nummela, P., Thiel, A., Lehtonen, R., Jarvinen, P., Jarvinen, H., Aaltonen, L.A., Lepisto, A., Hautaniemi, S., and Ristimaki, A. (2017). Multiple components of PKA and TGF-beta pathways are mutated in pseudomyxoma peritonei. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174898"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.humpath.2014.04.018","article-title":"GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival","volume":"45","author":"Singhi","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/jhg.2013.132","article-title":"Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: A comprehensive genetic profiling and survival analysis","volume":"59","author":"Sio","year":"2014","journal-title":"J. Hum. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.trsl.2015.03.004","article-title":"Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth","volume":"166","author":"Dilly","year":"2015","journal-title":"Transl. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: Weaving a tumorigenic web","volume":"11","author":"Grabocka","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jss.2012.10.053","article-title":"Kras mutations and p53 overexpression in pseudomyxoma peritonei: Association with phenotype and prognosis","volume":"180","author":"Shetty","year":"2013","journal-title":"J. Surg. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00432-020-03321-8","article-title":"The biological basis and function of GNAS mutation in pseudomyxoma peritonei: A review","volume":"146","author":"Lin","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/bjc.2013.47","article-title":"Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms","volume":"108","author":"Nishikawa","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e003109","DOI":"10.1136\/jitc-2021-003109","article-title":"Peptide vaccine targeting mutated GNAS: A potential novel treatment for pseudomyxoma peritonei","volume":"9","author":"Flatmark","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/his.13986","article-title":"Mutation profile of high-grade appendiceal mucinous neoplasm","volume":"76","author":"Liao","year":"2020","journal-title":"Histopathology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.12659\/AJCR.903581","article-title":"KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing","volume":"18","author":"Matson","year":"2017","journal-title":"Am. J. Case Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-016-0877-x","article-title":"GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: A clinical and translational study","volume":"14","author":"Pietrantonio","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00428-020-02906-5","article-title":"Molecular and clinicopathological features of appendiceal mucinous neoplasms","volume":"478","author":"Yanai","year":"2021","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1373\/clinchem.2014.225565","article-title":"Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations","volume":"60","author":"Liu","year":"2014","journal-title":"Clin. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lung, M.S., Mitchell, C.A., Doyle, M.A., Lynch, A.C., Gorringe, K.L., Bowtell, D.D.L., Australian Ovarian Cancer Study Group, Campbell, I.G., and Trainer, A.H. (2020). Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6705-y"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1158\/1078-0432.CCR-18-3388","article-title":"Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer","volume":"25","author":"Tokunaga","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.humpath.2018.11.011","article-title":"Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms","volume":"85","author":"Zhu","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_52","first-page":"PO.17.00302","article-title":"Genomic Landscape of Appendiceal Neoplasms","volume":"2","author":"Ang","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2019.12.008","article-title":"Pathological prognostic factors of pseudomyxoma peritonei: Comprehensive clinicopathological analysis of 155 cases","volume":"97","author":"Yan","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1245\/s10434-020-08841-8","article-title":"Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction\/HIPEC","volume":"27","author":"Moaven","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1245\/s10434-020-08210-5","article-title":"Prognostic Molecular Classification of Appendiceal Mucinous Neoplasms Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"27","author":"Su","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbagen.2014.05.003","article-title":"Mucins: A biologically relevant glycan barrier in mucosal protection","volume":"1850","author":"Corfield","year":"2015","journal-title":"Biochim. et Biophys. Acta"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: Function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2017.12.006","article-title":"Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets","volume":"122","author":"Dhanisha","year":"2018","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nri.2016.88","article-title":"Immunological aspects of intestinal mucus and mucins","volume":"16","author":"Johansson","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-011520-105053","article-title":"Mucins and the Microbiome","volume":"89","author":"Hansson","year":"2020","journal-title":"Annu. Rev. Biochem."},{"key":"ref_61","first-page":"958","article-title":"MUC2 is a molecular marker for pseudomyxoma peritonei","volume":"15","author":"Hacker","year":"2002","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol."},{"key":"ref_62","first-page":"D1216","article-title":"Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer?","volume":"6","author":"Pigny","year":"2001","journal-title":"Front. Biosci. A J. Virtual Libr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.2147\/CMAR.S324982","article-title":"The Biological Synthesis and the Function of Mucin 2 in Pseudomyxoma Peritonei","volume":"13","author":"Lin","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0002-9440(10)64211-3","article-title":"Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells","volume":"161","author":"Tomlinson","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7150\/ijms.16422","article-title":"Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP)","volume":"14","author":"Pillai","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000323137","article-title":"Immunohistochemical and biochemical characterization of mucin in pseudomyxoma peritonei: A case study","volume":"5","author":"Mall","year":"2011","journal-title":"Case Rep. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e108647","DOI":"10.15252\/embj.2021108647","article-title":"Dynamic EMT: A multi-tool for tumor progression","volume":"40","author":"Brabletz","year":"2021","journal-title":"EMBO J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.prp.2015.05.010","article-title":"Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review","volume":"211","author":"Cao","year":"2015","journal-title":"Pathol. Res. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41419-022-04514-4","article-title":"Estrogen receptor beta promotes lung cancer invasion via increasing CXCR4 expression","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Loret, N., Denys, H., Tummers, P., and Berx, G. (2019). The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. Cancers, 11.","DOI":"10.3390\/cancers11060838"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","article-title":"EMT, MET, Plasticity, and Tumor Metastasis","volume":"30","author":"Bakir","year":"2020","journal-title":"Trends Cell Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35000034","article-title":"The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells","volume":"2","author":"Batlle","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/sj.onc.1208429","article-title":"DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells","volume":"24","author":"Eger","year":"2005","journal-title":"Oncogene"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","article-title":"Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis","volume":"117","author":"Yang","year":"2004","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/sj.bjc.6603398","article-title":"A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei","volume":"95","author":"Bibi","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/pin.12157","article-title":"Prognostic significance of single isolated cells with decreased E-cadherin expression in pseudomyxoma peritonei","volume":"64","author":"Koh","year":"2014","journal-title":"Pathol. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1074\/jbc.M111.295964","article-title":"Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition","volume":"287","author":"Xiong","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.aaa4972","article-title":"Cancer and the microbiota","volume":"348","author":"Garrett","year":"2015","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.gpb.2017.06.002","article-title":"Human Gut Microbiota and Gastrointestinal Cancer","volume":"16","author":"Meng","year":"2018","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jfma.2019.01.002","article-title":"Microbiota and gastrointestinal cancer","volume":"118","author":"Weng","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1245\/s10434-007-9778-9","article-title":"Pseudomyxoma peritonei: Is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis","volume":"15","author":"Liu","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1750-1172-8-105","article-title":"A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei","volume":"8","author":"Gilbreath","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e01297-15","DOI":"10.1128\/genomeA.01297-15","article-title":"A Novel Member of Chitinophagaceae Isolated from a Human Peritoneal Tumor","volume":"3","author":"Lo","year":"2015","journal-title":"Genome Announc."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Villarejo-Campos, P., Garc\u00eda-Arranz, M., Qian, S., Jim\u00e9nez de Los Galanes, S., Dom\u00ednguez-Prieto, V., V\u00e9lez-Pinto, J.F., Guijo Castellano, I., Jim\u00e9nez-Fuertes, M., Guadalajara, H., and Garc\u00eda-Olmo, D. (2023). Under the Hood: Understanding the Features of Mucin in Pseudomyxoma Peritonei. J. Clin. Med., 12.","DOI":"10.20944\/preprints202305.1183.v1"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0925-4439(98)00010-6","article-title":"Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria","volume":"1406","author":"Dohrman","year":"1998","journal-title":"Biochim. et Biophys. Acta"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1158\/1078-0432.CCR-13-0616","article-title":"Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects beta-catenin distribution","volume":"19","author":"Testerman","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1158\/0008-5472.CAN-05-0718","article-title":"E-cadherin regulates the association between beta-catenin and actinin-4","volume":"65","author":"Hayashida","year":"2005","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.sla.0000133183.15705.71","article-title":"Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy","volume":"240","author":"Glehen","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_91","first-page":"868","article-title":"Survival of patients with pseudomyxoma peritonei treated by serial debulking","volume":"12","year":"2010","journal-title":"Color. Dis. Off. J. Assoc. Coloproctol. Great Br. Irel."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.soc.2018.02.009","article-title":"Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers","volume":"27","author":"Kusamura","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/bjs.9674","article-title":"Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"101","author":"Kusamura","year":"2014","journal-title":"Br. J. Surg."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1055-3207(03)00048-6","article-title":"Peritonectomy procedures","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1177\/030089160108700415","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome","volume":"87","author":"Sugarbaker","year":"2001","journal-title":"Tumori"},{"key":"ref_98","first-page":"1035","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours","volume":"42","author":"Ansari","year":"2016","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The transport barrier in intraperitoneal therapy","volume":"288","author":"Flessner","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#","article-title":"Selective heat sensitivity of cancer cells. Biochemical and clinical studies","volume":"20","author":"Cavaliere","year":"1967","journal-title":"Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1055-3207(03)00029-2","article-title":"Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents","volume":"12","author":"Sticca","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_103","first-page":"605","article-title":"Differential response of normal and tumor microcirculation to hyperthermia","volume":"44","author":"Dudar","year":"1984","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/1097-0142(197706)39:6<2637::AID-CNCR2820390650>3.0.CO;2-S","article-title":"Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis","volume":"39","author":"Overgaard","year":"1977","journal-title":"Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002800050721","article-title":"Hyperthermic intraperitoneal doxorubicin: Pharmacokinetics, metabolism, and tissue distribution in a rat model","volume":"41","author":"Jacquet","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_106","first-page":"39","article-title":"Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis","volume":"Volume 169","author":"Tsiftsis","year":"2007","journal-title":"Advances in Peritoneal Surface Oncology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1593\/neo.03205","article-title":"A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance","volume":"6","author":"Secomb","year":"2004","journal-title":"Neoplasia"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: Rationale and technique","volume":"2","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","article-title":"A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers","volume":"15","author":"Stewart","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","article-title":"A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors","volume":"226","author":"Levine","year":"2018","journal-title":"J. Am. Coll Surg."},{"key":"ref_113","first-page":"53","article-title":"Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: From laboratory bench to bedside","volume":"Volume 169","author":"Tsiftsis","year":"2007","journal-title":"Advances in Peritoneal Surface Oncology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-010-1460-4","article-title":"Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis","volume":"68","author":"Stuart","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.suronc.2019.03.004","article-title":"Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei","volume":"29","author":"Benhaim","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1245\/s10434-015-5019-9","article-title":"Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?","volume":"23","author":"Delhorme","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ejso.2010.09.004","article-title":"Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"36","author":"Alves","year":"2010","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10147-012-0397-5","article-title":"Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis","volume":"18","author":"Chua","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ejso.2017.09.002","article-title":"Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination","volume":"43","author":"Huang","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.amjsurg.2015.03.008","article-title":"Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: Assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis","volume":"210","author":"Lam","year":"2015","journal-title":"Am. J. Surg."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/02656736.2015.1135485","article-title":"Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?","volume":"32","author":"Tan","year":"2016","journal-title":"Int. J. Hyperth."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02523654","article-title":"Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome","volume":"7","author":"Pestieau","year":"2000","journal-title":"Ann. Surg. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"bcr2015211076","DOI":"10.1136\/bcr-2015-211076","article-title":"Pseudomyxoma peritonei with intrathoracic extension: A rare disease with rarer presentation from low-grade mucinous adenocarcinoma of the appendix","volume":"2016","author":"Ghosh","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/0959-8049(96)00178-5","article-title":"Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin","volume":"32A","author":"Zoetmulder","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/archsurg.2009.166","article-title":"Simultaneous bicavitary hyperthermic chemoperfusion in the management of pseudomyxoma peritonei with synchronous pleural extension","volume":"144","author":"Senthil","year":"2009","journal-title":"Arch. Surg."},{"key":"ref_126","first-page":"372","article-title":"Cytoreductive surgery plus bicavitary chemohyperthermia as treatment of pseudomixoma peritonei with pleural extension. A case report and review of the literature","volume":"85","author":"Saladino","year":"2014","journal-title":"Ann. Ital. Di Chir."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/02656736.2017.1300944","article-title":"Haemodynamic changes during hyperthermic intra-thoracic chemotherapy for pseudomyxoma peritonei","volume":"33","author":"Bell","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"102375","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality","volume":"105","author":"Kerr","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/SLA.0b013e31818eec64","article-title":"Pseudomyxoma peritonei: Biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"249","author":"Baratti","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jso.23547","article-title":"Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"109","author":"Blackham","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_132","first-page":"3","article-title":"Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"7","author":"Cummins","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejso.2015.01.005","article-title":"Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA)","volume":"41","author":"Milovanov","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/SLA.0b013e31819ec7e3","article-title":"Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: Long-term follow-up of the Mayo Clinic experience","volume":"249","author":"Schomas","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","article-title":"Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms","volume":"22","author":"Choe","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00464-012-2148-0","article-title":"Description of a novel approach for intraperitoneal drug delivery and the related device","volume":"26","author":"Hetzel","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/02656736.2019.1704891","article-title":"PIPAC versus HIPEC: Cisplatin spatial distribution and diffusion in a swine model","volume":"37","author":"Davigo","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1245\/s10434-021-10899-x","article-title":"Is PIPAC a New Summit for Peritoneal Disease Treatment or are we Lost in the Snowstorm?","volume":"29","author":"Badgwell","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.21037\/jgo-20-257","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review","volume":"12","author":"Lurvink","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: First evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","article-title":"Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: Proof of concept","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.gore.2014.10.001","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report","volume":"10","author":"Tempfer","year":"2014","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_144","first-page":"959","article-title":"Transient hyperglycemia following intra-peritoneal irrigation with 5% glucose in a patient with pseudomyxoma peritonei","volume":"56","author":"Mieda","year":"2007","journal-title":"Jpn. J. Anesthesiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/gyno.1997.4657","article-title":"Acute hyperglycemia following intraperitoneal irrigation with 10% dextrose in a patient with pseudomyxoma peritonei","volume":"65","author":"Roy","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00540-008-0612-8","article-title":"Critical alkalosis following intraperitoneal irrigation with sodium bicarbonate in a patient with pseudomyxoma peritonei","volume":"22","author":"Shirasawa","year":"2008","journal-title":"J. Anesth."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"33329","DOI":"10.18632\/oncotarget.5259","article-title":"Depletion of mucin in mucin-producing human gastrointestinal carcinoma: Results from in vitro and in vivo studies with bromelain and N-acetylcysteine","volume":"6","author":"Amini","year":"2015","journal-title":"Oncotarget"},{"key":"ref_148","first-page":"92","article-title":"Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: Significance of combination therapy","volume":"33","author":"Amini","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.28380","article-title":"A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei","volume":"134","author":"Pillai","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejso.2019.10.033","article-title":"A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study","volume":"47","author":"Valle","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_151","first-page":"869","article-title":"The cysteine proteinases of the pineapple plant","volume":"266","author":"Rowan","year":"1990","journal-title":"Biochem. J."},{"key":"ref_152","first-page":"859","article-title":"Mucolytics, expectorants, and mucokinetic medications","volume":"52","author":"Rubin","year":"2007","journal-title":"Respir. Care"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1042\/BST0370877","article-title":"Regulation of mucin expression in respiratory diseases","volume":"37","author":"Turner","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Mekkawy, A.H., Breakeit, M., Pillai, K., Badar, S., Akhter, J., Valle, S.J., and Morris, D.L. (2023). Intraperitoneal BromAc(\u00ae) Does Not Interfere with the Healing of Colon Anastomosis. Cancers, 15.","DOI":"10.3390\/cancers15133321"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Andersson, Y., Fleten, K.G., Abrahamsen, T.W., Reed, W., Davidson, B., and Flatmark, K. (2021). Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale. Cancers, 13.","DOI":"10.3390\/cancers13112819"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ajpath.2014.03.004","article-title":"Orthotopic animal model of pseudomyxoma peritonei: An in vivo model to test anti-angiogenic drug effects","volume":"184","author":"Dohan","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.physiol.70.113006.100441","article-title":"Regulation of airway mucin gene expression","volume":"70","author":"Thai","year":"2008","journal-title":"Annu. Rev. Physiol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1245\/s10434-012-2242-5","article-title":"Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei","volume":"19","author":"Choudry","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.3390\/curroncol29050289","article-title":"The Role of Microorganisms in Appendiceal Pseudomyxoma Peritonei: A Review","volume":"29","author":"Khamzina","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.ejso.2019.01.223","article-title":"Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment","volume":"45","author":"Merrell","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/290145a0","article-title":"Immunotoxins: Hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells","volume":"290","author":"Blythman","year":"1981","journal-title":"Nature"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","article-title":"Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers","volume":"94","author":"Went","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ijc.20371","article-title":"Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin","volume":"112","author":"Andersson","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3390\/toxins5081486","article-title":"Immunotoxins: The Role of the Toxin","volume":"5","author":"Antignani","year":"2013","journal-title":"Toxins"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.28158","article-title":"Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies","volume":"133","author":"Flatmark","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejso.2019.04.014","article-title":"ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis","volume":"47","author":"Froysnes","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1245\/s10434-017-5814-6","article-title":"Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial","volume":"24","author":"Froysnes","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1alpha pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin B"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Zimna, A., and Kurpisz, M. (2015). Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. Biomed. Res. Int., 2015.","DOI":"10.1155\/2015\/549412"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.semcancer.2020.09.011","article-title":"Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds","volume":"80","author":"Ma","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejmech.2012.01.033","article-title":"Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors","volume":"49","author":"Xia","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/path.2863","article-title":"Hypoxia-inducible factor-1 signalling promotes goblet cell hyperplasia in airway epithelium","volume":"224","author":"Polosukhin","year":"2011","journal-title":"J. Pathol."},{"key":"ref_174","first-page":"419","article-title":"Hypoxia induces mucin expression and secretion in human bronchial epithelial cells","volume":"160","author":"Zhou","year":"2012","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1076500","DOI":"10.3389\/fonc.2023.1076500","article-title":"Intraoperative oxygen tension and redox homeostasis in Pseudomyxoma peritonei: A short case series","volume":"13","author":"Bura","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.006","article-title":"Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors","volume":"169","author":"Dilly","year":"2016","journal-title":"Transl. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-022-00297-8","article-title":"Current insight into the regulation of PD-L1 in cancer","volume":"11","author":"Liu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4049\/jimmunol.1701044","article-title":"Inhibitors of the PD-1 Pathway in Tumor Therapy","volume":"200","author":"LaFleur","year":"2018","journal-title":"J. Immunol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-017-0541-9","article-title":"Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Kusamura, S., Busico, A., Conca, E., Capone, I., Agnelli, L., Lorenzini, D., Brich, S., Angelini, M., Volpi, C.C., and Trupia, D.V. (2023). A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei. Biomedicines, 11.","DOI":"10.3390\/biomedicines11072049"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-021-00231-4","article-title":"Recent advances in Lynch syndrome","volume":"10","author":"Li","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1073\/pnas.95.10.5718","article-title":"Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells","volume":"95","author":"Li","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"32258","DOI":"10.1074\/jbc.M204862200","article-title":"Induction of MUC2 and MUC5AC Mucins by Factors of the Epidermal Growth Factor (EGF) Family Is Mediated by EGF Receptor\/Ras\/Raf\/Extracellular Signal-regulated Kinase Cascade and Sp1*","volume":"277","author":"Perrais","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Kuracha, M.R., Thomas, P., Loggie, B.W., and Govindarajan, V. (2017). Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179510"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40164-023-00465-4","article-title":"Antitumor effect of a small-molecule inhibitor of KRAS(G12D) in xenograft models of mucinous appendicular neoplasms","volume":"12","author":"Bura","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/imt-2016-0141","article-title":"Recent progress in GM-CSF-based cancer immunotherapy","volume":"9","author":"Yan","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-17-3757","article-title":"Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients","volume":"24","author":"Khanna","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coph.2016.06.009","article-title":"A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1\u03b1 driven immunosuppression and improve immunotherapies of cancer","volume":"29","author":"Hatfield","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.18632\/oncotarget.3198","article-title":"Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines","volume":"6","author":"Roberts","year":"2015","journal-title":"Oncotarget"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Noguchi, R., Yoshimatsu, Y., Sin, Y., Ono, T., Tsuchiya, R., Yoshida, H., Kiyono, T., Yonemura, Y., and Kondo, T. (2022). Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei. J. Pers. Med., 12.","DOI":"10.3390\/jpm12020258"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13577-023-01015-0","article-title":"Establishment and characterization of NCC-PMP2-C1: A novel patient-derived cell line of pseudomyxoma peritonei with signet ring cells","volume":"37","author":"Noguchi","year":"2024","journal-title":"Hum. Cell"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41575-022-00631-9","article-title":"Akkermansia muciniphila: Paradigm for next-generation beneficial microorganisms","volume":"19","author":"Cani","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1758835920928233","DOI":"10.1177\/1758835920928233","article-title":"The role of mucin cell-free DNA detection as a new marker for the study of acellular pseudomyxoma peritonei of appendicular origin by liquid biopsy","volume":"12","author":"Villarejo","year":"2020","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1406\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:56Z","timestamp":1760106176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/7\/1406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":197,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16071406"],"URL":"https:\/\/doi.org\/10.3390\/cancers16071406","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]}}}